Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Equity Average (2022 - 2025)

Zentalis Pharmaceuticals has reported Equity Average over the past 4 years, most recently at $234.5 million for Q4 2025.

  • Quarterly results put Equity Average at $234.5 million for Q4 2025, down 32.17% from a year ago — trailing twelve months through Dec 2025 was $234.5 million (down 32.17% YoY), and the annual figure for FY2025 was $276.7 million, down 28.56%.
  • Equity Average for Q4 2025 was $234.5 million at Zentalis Pharmaceuticals, down from $263.7 million in the prior quarter.
  • Over the last five years, Equity Average for ZNTL hit a ceiling of $502.6 million in Q3 2023 and a floor of $234.5 million in Q4 2025.
  • Median Equity Average over the past 4 years was $409.8 million (2023), compared with a mean of $385.7 million.
  • Biggest five-year swings in Equity Average: increased 15.28% in 2023 and later crashed 32.27% in 2025.
  • Zentalis Pharmaceuticals' Equity Average stood at $431.4 million in 2022, then increased by 6.55% to $459.6 million in 2023, then dropped by 24.78% to $345.8 million in 2024, then tumbled by 32.17% to $234.5 million in 2025.
  • The last three reported values for Equity Average were $234.5 million (Q4 2025), $263.7 million (Q3 2025), and $284.9 million (Q2 2025) per Business Quant data.